The chlorhexidine gluconate (CHG) dressing market is set for substantial growth, with projections indicating a rise from USD 952.1 million in 2023 to over USD 1.5 billion by 2033. This represents a compound annual growth rate (CAGR) of 4.4% throughout the forecast period.
The market’s expansion is driven by the heightened emphasis on infection prevention in healthcare settings. With a growing focus on preventing surgical site infections and other wound-related infections, healthcare practitioners and organizations are increasingly adopting chlorhexidine gluconate dressings as a key preventative strategy.
Chlorhexidine gluconate dressings are renowned for their effectiveness in reducing bacterial load and minimizing the risk of wound infections. Their rising popularity reflects a broader shift towards improved infection control practices and patient safety measures in medical environments.
The healthcare industries of emerging nations, notably those in Asia-Pacific and Latin America, are expanding rapidly. Increased investments in healthcare infrastructure, rising disposable incomes, and expanding knowledge of advanced wound care are all expected to contribute to the growth of the chlorhexidine gluconate dressing market in these areas.
The acceptance and use of chlorhexidine gluconate dressing can be strongly influenced by the formulation of guidelines and protocols by healthcare authorities and organisations. The need for chlorhexidine gluconate dressing may increase as regulatory authorities emphasize infection control and standardize wound care practices.
The industry is expanding as a result of hospitals performing an increasing number of surgical operations. Clinical situations involving surgical infections are challenging and complex. As the skin’s surface is thought to be a possible source of germs, it is crucial to clean and prepare the skin before surgery. Currently, the most used skin preparation agent in healthcare settings is chlorhexidine gluconate solution. Additionally, the most typical hospital acquired infections in patients having surgery are caused by surgical site infections. Patients who develop surgical site infections stay in hospitals for longer periods of time and are far more likely to require intensive care unit (ICU) treatment, which drives up costs.
Key Takeaways:
- The chlorhexidine gluconate dressing industry in the United States is predicted to reach US$ 401.3 million by 2033, increasing at a 4.5% CAGR.
- The chlorhexidine gluconate dressing industry in the United Kingdom is estimated to reach a market size of US$ 36.6 million, expanding at a CAGR of 3.9% by 2033.
- During the forecast period, the chlorhexidine gluconate dressing industry in China is expected to reach a market value of US$ 168.0 million, securing a 5.6% CAGR.
- The chlorhexidine gluconate dressing industry in Japan is predicted to reach US$ 118.2 million by 2033, increasing at a 5.4% CAGR.
- South Korea’s chlorhexidine gluconate dressing industry is predicted to achieve a market share of US$ 37.5 million, rising at a 5.0% CAGR during the forecast period.
- With a CAGR of 4.1% from 2023 to 2033, the CHG-impregnated gauze dressings segment is expected to dominate the chlorhexidine gluconate dressing industry.
- With a CAGR of 4.7% from 2023 to 2033, the Surgical Site Infection (SSIs) dominate the chlorhexidine gluconate dressing industry.
- With a CAGR of 4.3% from 2023 to 2033, the hospital is expected to dominate the chlorhexidine gluconate dressing industry.
How Does the Competition Look in the Chlorhexidine Gluconate Dressing Market?
The chlorhexidine gluconate dressing sector is a very competitive one, with many firms fighting for market share. Several significant participants in this industry comprise The 3M Company, Johnson Johnson, Avery Dennison Corporation, Covalon Technologies Ltd., Zheijiang Hongyu Medical Commodity Co., Ltd., Becton Dickenson Company, Medline Industries, Cardinal Health, Integra LifeSciences, Smith Nephew, B Braun melsungen AG among other companies.
The major businesses are heavily spending in RD efforts to create innovative and inventive goods with enhanced effectiveness, dependability, and affordability. They are also focusing on expanding their product line and strengthening their distribution methods in order to fulfil shifting consumer expectations.
Tactical alliances and partnerships with other companies are becoming more common in the industry, allowing parties to leverage one another’s strengths and expand their market influence.
Leading firms use consolidation and mergers to strengthen their market position and gain entry into new markets. The sector is expanding significantly in developing economies, particularly in India and China.
To boost their presence in these regions, major companies are expanding their distribution networks and building regional manufacturing sites. They are also concentrating on offering cost-effective solutions to customers in these markets in order to get a competitive advantage.
Key Players:
- The 3M Company
- Johnson Johnson
- Avery Dennison Corporation
- Covalon Technologies Ltd.
- Zheijiang Hongyu Medical Commodity Co., Ltd.
- Becton Dickenson Company
- Medline Industries
- Cardinal Health
- Integra LifeSciences
- Smith Nephew
- B Braun melsungen AG
Key Developments in the Chlorhexidine Gluconate Dressing Market:
- On March 17, 2022, Chlorhexidine Gluconate (CHG), the top antiseptic on the market, was used by Cardinal Health to introduce the first surgical incise drape.
- ON, Nov. 21, 2022, in a two-year quality improvement study recently released by Intermountain Primary Children’s Hospital, Covalon Technologies Ltd. reported that their SurgiClear dressing was a critical component of an infection prevention bundle that drastically decreased surgical wound infections.
Chlorhexidine Gluconate Dressing Market Segmentation:
By Dressing type:
- CHG-impregnated Gel
- CHG-impregnated Gauze
- CHG-impregnated Film
- CHG-Impregnated Foam
- Other Dressings
By Application:
- Surgical Site Infection (SSIs)
- Catheter-Related Blood Stream Infections (CRBSI)
- Catheter-Associated Urinary Tract Infections (CAUTI)
- Others (Burns, Ulcers, etc.)
By End Users:
- Hospitals
- Clinics
- Diagnostic Centers
- Homecare Settings
- Ambulatory Surgical Centers
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
